First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers
High Grade Serous Adenocarcinoma of Ovary